Skip to main content

Table 1 Baseline characteristics of matched population

From: Risk of incident atrial fibrillation in patients presenting with retinal artery or vein occlusion: a nationwide cohort study

  Overall Retinal arterial and vein occlusion
  With retinal vascular occlusion Controls p-value Arterial Vein p-value for difference between retinal artery and vein occlusion
n 1368 6840   706 529  
Median age, years (IQR) 71.4 (61.2–79.8) 71.4 (61.2–79.8) * 70.7 (61.2–78.7) 73.4 (62.3–81.3) <  0.01
Male 648 (47.3%) 3240 (47.3%) * 351 (49.7%) 241 (45.6%) 0.150
Diabetes 115 (8.4%) 368 (5.4%) <  0.01 59 (8.4%) 50 (9.5%) 0.502
Heart failure 67 (4.9%) 168 (2.5%) <  0.01 34 (4.8%) 29 (5.5%) 0.599
Hypertension 391 (28.6%) 1188 (17.4%) <  0.01 183 (25.9%) 160 (30.2%) 0.093
Stroke/TE/TIA 257 (18.8%) 395 (5.8%) <  0.01 161 (22.8%) 62 (11.7%) <  0.01
Vascular disease 148 (10.8%) 416 (6.1%) <  0.01 92 (13%) 45 (8.5%) 0.012
Acetylsalicylic acid 514 (37.6%) 1236 (18.1%) <  0.01 277 (39.2%) 190 (35.9%) 0.234
Antiadrenergic 24 (1.8%) 61 (0.9%) <  0.01 10 (1.4%) 13 (2.5%) 0.181
Beta blockers 234 (17.1%) 753 (11%) <  0.01 113 (16%) 94 (17.8%) 0.412
Calcium channel blockers 279 (20.4%) 831 (12.1%) <  0.01 138 (19.5%) 107 (20.2%) 0.767
Clopidogrel 22 (1.6%) 55 (0.8%) <  0.01 18 (2.5%) 3 (0.6%) <  0.01
Loop diuretics 185 (13.5%) 590 (8.6%) <  0.01 97 (13.7%) 77 (14.6%) 0.683
NSAID 235 (17.2%) 915 (13.4%) <  0.01 125 (17.7%) 84 (15.9%) 0.397
Non-loop diuretics 405 (29.6%) 1347 (19.7%) <  0.01 182 (25.8%) 170 (32.1%) 0.014
Dipyridamole 79 (5.8%) 108 (1.6%) <  0.01 54 (7.6%) 16 (3%) <  0.01
  1. *=not calculated; age and sex were parameters used for matching, hence the distribution between was similar. IQR Interquartile range